Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$110.81 /

+1.78 (+1.63%)

, ABC

AmerisourceBergen

$121.16 /

+0.69 (+0.57%)

04:55
04/22/21
04/22
04:55
04/22/21
04:55

American Academy of Neurology to hold a virtual meeting

73rd Annual Virtual Meeting of AAN will be held on April 17-22. Webcast Link

ABBV

AbbVie

$110.81 /

+1.78 (+1.63%)

ABC

AmerisourceBergen

$121.16 /

+0.69 (+0.57%)

ABT

Abbott

$122.61 /

+2.62 (+2.18%)

ACAD

Acadia Pharmaceuticals

$21.46 /

+0.67 (+3.22%)

ALNY

Alnylam

$137.67 /

+2 (+1.47%)

BIIB

Biogen

$269.13 /

-3.84 (-1.41%)

BMY

Bristol-Myers

$66.32 /

+0.265 (+0.40%)

BHVN

Biohaven Pharmaceutical

$75.13 /

+1.5 (+2.04%)

CPRX

Catalyst Pharmaceuticals

$4.52 /

+0.13 (+2.96%)

DGX

Quest Diagnostics

$130.08 /

+0.79 (+0.61%)

DNA

Bought by RHHBY

$94.97 /

+ (+0.00%)

HZNP

Horizon Therapeutics

$93.52 /

+2.45 (+2.69%)

LIVN

LivaNova

$83.05 /

+1.63 (+2.00%)

LLY

Eli Lilly

$191.00 /

+0.45 (+0.24%)

MDT

Medtronic

$130.19 /

+1.9 (+1.48%)

NVS

Novartis

$88.67 /

+0.84 (+0.96%)

NVTA

Invitae

$36.05 /

+1.795 (+5.24%)

PFE

Pfizer

$39.53 /

+0.5 (+1.28%)

PTCT

PTC Therapeutics

$45.78 /

-0.545 (-1.18%)

RETA

Reata Pharmaceuticals

$90.75 /

+1.17 (+1.31%)

SNY

Sanofi

$52.43 /

+0.44 (+0.85%)

SUPN

Supernus

$31.37 /

+0.61 (+1.98%)

TAK

Takeda Pharmaceutical

$16.93 /

+0.095 (+0.56%)

TEVA

Teva

$10.25 /

+0.135 (+1.33%)

TGTX

TG Therapeutics

$40.61 /

+0.64 (+1.60%)

ZGNX

Zogenix

$18.95 /

+0.09 (+0.48%)

AVDL

Avadel Pharmaceuticals

$8.46 /

+0.265 (+3.24%)

JNJ

Johnson & Johnson

$166.61 /

+0.16 (+0.10%)

  • 22

    Apr

  • 22

    Apr

  • 22

    Apr

  • 22

    Apr

  • 23

    Apr

  • 23

    Apr

  • 27

    Apr

  • 28

    Apr

  • 28

    Apr

  • 28

    Apr

  • 29

    Apr

  • 29

    Apr

  • 29

    Apr

  • 30

    Apr

  • 03

    May

  • 04

    May

  • 04

    May

  • 04

    May

  • 04

    May

  • 05

    May

  • 05

    May

  • 05

    May

  • 06

    May

  • 07

    May

  • 18

    May

  • 18

    May

  • 20

    May

  • 21

    May

  • 24

    May

  • 25

    May

  • 27

    May

  • 30

    May

  • 02

    Jun

  • 07

    Jun

  • 15

    Jun

  • 21

    Jul

  • 15

    Oct

  • 29

    Dec

  • 28

    Jan

  • 29

    Apr

  • 15

    May

  • 07

    Aug

  • 02

    Dec

  • 15

    Dec

  • 22

    Jan

  • 16

    Mar

ABBV AbbVie
$110.81 /

+1.78 (+1.63%)

04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/21/21 Citi
Citi opens '90-day positive catalyst' on AbbVie, reiterates Buy rating
04/06/21 RBC Capital
AbbVie transferred with an Outperform at RBC Capital
04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
ABC AmerisourceBergen
$121.16 /

+0.69 (+0.57%)

03/09/21 Baird
AmerisourceBergen remains top pick following results, says Baird
02/09/21 Mizuho
AmerisourceBergen price target raised to $114 from $104 at Mizuho
02/08/21 Cowen
AmerisourceBergen price target raised to $150 from $145 at Cowen
02/04/21 Evercore ISI
AmerisourceBergen upgraded to Outperform after Q1 report at Evercore ISI
ABT Abbott
$122.61 /

+2.62 (+2.18%)

04/15/21 Atlantic Equities
Atlantic Equities starts Abbott at Neutral
04/15/21 Atlantic Equities
Abbott initiated with a Neutral at Atlantic Equities
03/16/21 Piper Sandler
Abbott study challenging Abiomed's Impella halted, says Piper Sandler
03/10/21 Wells Fargo
Wells says Quidel Covid testing comments not a direct read through to Abbott
ACAD Acadia Pharmaceuticals
$21.46 /

+0.67 (+3.22%)

04/07/21 Needham
Acadia price target lowered to $30 from $44 at Needham
04/07/21 H.C. Wainwright
Acadia downgraded to Neutral from Buy at H.C. Wainwright
04/06/21 SVB Leerink
Acadia price target lowered to $31 from $63 at SVB Leerink
04/06/21 Jefferies
Acadia downgraded to Hold at Jefferies after dementia-related psychosis CRL
ALNY Alnylam
$137.67 /

+2 (+1.47%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
BIIB Biogen
$269.13 /

-3.84 (-1.41%)

04/19/21 Jefferies
Biogen 'may have best risk/reward among large caps' in 2021-23, says Jefferies
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
04/12/21 Oppenheimer
Sage Therapeutics data support 'enthusiasm' for SAGE-324 in ET, says Oppenheimer
04/12/21 Wedbush
Biogen price target raised to $245 from $236 at Wedbush
BMY Bristol-Myers
$66.32 /

+0.265 (+0.40%)

04/21/21 Citi
Citi opens '90-day catalyst watch' on Bristol-Myers, reiterates Buy
04/13/21 Truist
Bristol-Myers upgraded to Buy at Truist on improving pipeline asset visibility
04/13/21 Truist
Bristol-Myers upgraded to Buy from Hold at Truist
BHVN Biohaven Pharmaceutical
$75.13 /

+1.5 (+2.04%)

04/01/21 Piper Sandler
Piper migraine survey bearish for Amgen, bullish for Biohaven
03/11/21
Fly Intel: Top five analyst initiations
03/11/21 UBS
Biohaven Pharmaceutical initiated with a Buy at UBS
03/02/21 Mizuho
Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho
CPRX Catalyst Pharmaceuticals
$4.52 /

+0.13 (+2.96%)

03/16/21 Piper Sandler
Catalyst business continues to generate cash flow, says Piper Sandler
01/07/21 Piper Sandler
Piper says Catalyst's Firdapse commercial business performing as expected
01/06/21 Piper Sandler
Catalyst Firdapse commercial business performing as expected, says Piper Sandler
11/10/20 Piper Sandler
Catalyst Pharmaceuticals price target lowered to $5.50 from $6 at Piper Sandler
DGX Quest Diagnostics
$130.08 /

+0.79 (+0.61%)

03/12/21 Baird
Quest Diagnostics downgraded to Neutral from Outperform at Baird
01/29/21 Citi
Quest Diagnostics price target raised to $158 from $151 at Citi
12/17/20 Morgan Stanley
Morgan Stanley cuts Quest Diagnostics to Equal Weight ahead of 2022 slowdown
12/17/20 Morgan Stanley
Quest Diagnostics downgraded to Equal Weight from Overweight at Morgan Stanley
DNA Bought by RHHBY
$94.97 /

+ (+0.00%)

HZNP Horizon Therapeutics
$93.52 /

+2.45 (+2.69%)

03/25/21 Guggenheim
Horizon Therapeutics price target raised to $120 from $115 at Guggenheim
03/22/21
Fly Intel: Top five analyst initiations
03/22/21 Morgan Stanley
Horizon Therapeutics resumed with an Overweight at Morgan Stanley
03/18/21 Citi
Horizon Therapeutics price target raised to $120 from $116 at Citi
LIVN LivaNova
$83.05 /

+1.63 (+2.00%)

04/19/21 Piper Sandler
LivaNova HF enrollment milestone a key step toward approval, says Piper Sandler
04/13/21 Piper Sandler
LivaNova price target raised to $92 from $81 at Piper Sandler
03/03/21
Fly Intel: Top five analyst downgrades
03/03/21 Berenberg
Berenberg cuts LivaNova EPS forecasts on investments, downgrades to Hold
LLY Eli Lilly
$191.00 /

+0.45 (+0.24%)

04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
MDT Medtronic
$130.19 /

+1.9 (+1.48%)

04/15/21 Atlantic Equities
Atlantic Equities starts Medtronic at Overweight
04/15/21 Atlantic Equities
Medtronic initiated with an Overweight at Atlantic Equities
04/05/21 Citi
Citi opens positive catalyst watches on four medical supply stocks
02/24/21 Cowen
Medtronic price target raised to $135 from $120 at Cowen
NVS Novartis
$88.67 /

+0.84 (+0.96%)

04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
03/23/21 Societe Generale
Novartis price target raised to CHF 107 from CHF 104 at Societe Generale
03/22/21 Bernstein
Novartis initiated with a Market Perform at Bernstein
NVTA Invitae
$36.05 /

+1.795 (+5.24%)

04/05/21 Oppenheimer
Oppenheimer upgrades Invitae on valuation, sees potential high $50s stock
04/05/21 Oppenheimer
Invitae upgraded to Outperform from Perform at Oppenheimer
02/18/21 Ladenburg
Invitae upgraded to Buy with $58 price target at Ladenburg
02/18/21 Ladenburg
Invitae upgraded to Buy from Neutral at Ladenburg
PFE Pfizer
$39.53 /

+0.5 (+1.28%)

04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
04/09/21
Pfizer to host conference call
PTCT PTC Therapeutics
$45.78 /

-0.545 (-1.18%)

03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform from Underperform at RBC Capital
02/26/21 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald
02/12/21 BofA
PTC Therapeutics downgraded to Neutral from Buy at BofA
RETA Reata Pharmaceuticals
$90.75 /

+1.17 (+1.31%)

11/25/20 Citi
Reata Pharmaceuticals price target lowered to $234 from $260 at Citi
11/10/20 Cantor Fitzgerald
Reata Pharmaceuticals price target raised to $220 from $169 at Cantor Fitzgerald
11/10/20 Citi
Reata Pharmaceuticals price target raised to $260 from $244 at Citi
08/11/20 Cantor Fitzgerald
Reata Pharmaceuticals price target lowered to $169 from $275 at Cantor Fitzgerald
SNY Sanofi
$52.43 /

+0.44 (+0.85%)

04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
SUPN Supernus
$31.37 /

+0.61 (+1.98%)

04/13/21 Jefferies
Supernus upgraded to Buy after survey work at Jefferies
04/13/21 Jefferies
Supernus upgraded to Buy from Hold at Jefferies
02/03/21 Piper Sandler
Supernus price target raised to $35 from $30 at Piper Sandler
06/16/20 Piper Sandler
Supernus upgraded to Overweight from Neutral at Piper Sandler
TAK Takeda Pharmaceutical
$16.93 /

+0.095 (+0.56%)

04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
04/05/21
Fly Intel: Top five analyst downgrades
TEVA Teva
$10.25 /

+0.135 (+1.33%)

04/06/21 RBC Capital
Teva transferred with a Sector Perform at RBC Capital
01/26/21 Piper Sandler
Amarin in 'strong position' against Health Net, says Piper Sandler
12/21/20 Gabelli
Teva named 'Best Idea for 2021' at Gabelli
11/27/20 H.C. Wainwright
Corcept Therapeutics price target raised to $32 from $22 at H.C. Wainwright
TGTX TG Therapeutics
$40.61 /

+0.64 (+1.60%)

04/20/21
Fly Intel: Top five analyst initiations
04/20/21 Goldman Sachs
TG Therapeutics initiated with a Neutral at Goldman Sachs
04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
ZGNX Zogenix
$18.95 /

+0.09 (+0.48%)

04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
04/06/21 Citi
Longboard Pharmaceuticals initiated with a Buy at Citi
02/03/21 Mizuho
Jazz deal for GW Pharma has positive read through to Zogenix, says Mizuho
12/04/20 Mizuho
Zogenix collaboration step in right direction, says Mizuho
AVDL Avadel Pharmaceuticals
$8.46 /

+0.265 (+3.24%)

03/10/21 H.C. Wainwright
Avadel Pharmaceuticals price target raised to $17 from $15 at H.C. Wainwright
01/25/21 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy rating at Craig-Hallum
08/28/20 Oppenheimer
Uwarranted pressure creates buying opportunity for Avadel, says Oppenheimer
08/28/20 SVB Leerink
Avadel selloff on Jazz competition worries overdone, says SVB Leerink
JNJ Johnson & Johnson
$166.61 /

+0.16 (+0.10%)

04/19/21 Chardan
Chardan sees J&J moving forward with Emergent if observations are minor
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs

TODAY'S FREE FLY STORIES

Periodicals
Used cars, online car dealers 'are red hot,' Barron's says » 11:09
05/15/21
05/15
11:09
05/15/21
11:09
CVNA

Carvana

$237.35 /

+13.385 (+5.98%)

, VRM

Vroom

$38.82 /

+2.7099 (+7.50%)

, SFT

Shift

$7.66 /

+0.36 (+4.93%)

In one of the stranger…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VRM Vroom
$38.82 /

+2.7099 (+7.50%)

SFT Shift
$7.66 /

+0.36 (+4.93%)

CVNA Carvana
$237.35 /

+13.385 (+5.98%)

CVNA Carvana
$237.35 /

+13.385 (+5.98%)

05/12/21 Deutsche Bank
Carvana price target raised to $283 from $280 at Deutsche Bank
05/11/21 Citi
Carvana price target raised to $375 from $350 at Citi
05/07/21 JMP Securities
Carvana price target raised to $326 from $290 at JMP Securities
05/03/21
Fly Intel: Top five analyst upgrades
VRM Vroom
$38.82 /

+2.7099 (+7.50%)

05/13/21 Raymond James
Vroom price target raised to $53 from $47 at Raymond James
05/13/21 JMP Securities
Vroom price target raised to $55 from $48 at JMP Securities
05/13/21 Piper Sandler
Vroom price target lowered to $58 from $60 at Piper Sandler
04/13/21 Wedbush
Vroom added to Best List Ideas at Wedbush
SFT Shift
$7.66 /

+0.36 (+4.93%)

05/04/21 Wedbush
Shift upgraded to Neutral from Underperform at Wedbush
03/09/21 Benchmark
Benchmark sees Shift on a 'positive path,' upgrades to Buy
03/09/21 Benchmark
Shift upgraded to Buy from Hold at Benchmark
01/25/21 DA Davidson
Shift initiated with a Buy at DA Davidson
VRM Vroom
$38.82 /

+2.7099 (+7.50%)

SFT Shift
$7.66 /

+0.36 (+4.93%)

CVNA Carvana
$237.35 /

+13.385 (+5.98%)

  • 07
    Dec
  • 02
    Dec
  • 11
    Sep
  • 09
    Jun
  • 19
    May
CVNA Carvana
$237.35 /

+13.385 (+5.98%)

VRM Vroom
$38.82 /

+2.7099 (+7.50%)

SFT Shift
$7.66 /

+0.36 (+4.93%)

CVNA Carvana
$237.35 /

+13.385 (+5.98%)

VRM Vroom
$38.82 /

+2.7099 (+7.50%)

SFT Shift
$7.66 /

+0.36 (+4.93%)

CVNA Carvana
$237.35 /

+13.385 (+5.98%)

Periodicals
Electric lawn tools good for Stanley Black & Decker, Barron's says » 11:03
05/15/21
05/15
11:03
05/15/21
11:03
SWK

Stanley Black & Decker

$216.33 /

+0.245 (+0.11%)

Tools that run on…

Tools that run on batteries are less noisy and noxious than those that use gasoline, and the shift to them is well under way, Jack Hough writes in this week's edition of Barron's. Electrification is good for business, at least for Stanley Black & Decker, the authors notes. Reference Link

ShowHide Related Items >><<
SWK Stanley Black & Decker
$216.33 /

+0.245 (+0.11%)

SWK Stanley Black & Decker
$216.33 /

+0.245 (+0.11%)

04/13/21 Deutsche Bank
Stanley Black & Decker price target raised to $221 from $215 at Deutsche Bank
04/07/21 JPMorgan
Stanley Black & Decker price target raised to $206 from $200 at JPMorgan
04/06/21 Barclays
Stanley Black & Decker price target raised to $219 from $214 at Barclays
03/12/21
Fly Intel: Top five analyst upgrades
SWK Stanley Black & Decker
$216.33 /

+0.245 (+0.11%)

SWK Stanley Black & Decker
$216.33 /

+0.245 (+0.11%)

SWK Stanley Black & Decker
$216.33 /

+0.245 (+0.11%)

Periodicals
Realogy 'an unlikely hero' of realty revolution, stock looks cheap,Barron's says » 10:59
05/15/21
05/15
10:59
05/15/21
10:59
RLGY

Realogy

$17.86 /

+0.64 (+3.72%)

Shares of the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RLGY Realogy
$17.86 /

+0.64 (+3.72%)

RLGY Realogy
$17.86 /

+0.64 (+3.72%)

01/29/21 Barclays
Realogy reinstated with an Underweight at Barclays
12/21/20 JPMorgan
JPMorgan changes ratings in REIT, Real Estate Services sectors into 2021
12/21/20 JPMorgan
Realogy upgraded to Neutral from Underweight at JPMorgan
12/18/20 Compass Point
Realogy price target raised to $19 from $16 at Compass Point
RLGY Realogy
$17.86 /

+0.64 (+3.72%)

Periodicals
DuPont stock looks like a buy, Barron's says » 10:55
05/15/21
05/15
10:55
05/15/21
10:55
DD

DuPont

$83.27 /

+1.63 (+2.00%)

Chemical stocks have been…

Chemical stocks have been soaring, but DuPont has been lagging behind its peers, Al Root writes in this week's edition of Barron's. Its shares look like a smart play on the coming phase of the economic recovery as it begins to play catch-up, the author contends. Reference Link

ShowHide Related Items >><<
DD DuPont
$83.27 /

+1.63 (+2.00%)

DD DuPont
$83.27 /

+1.63 (+2.00%)

05/14/21 Argus
DuPont price target raised to $93 from $81 at Argus
05/11/21 Goldman Sachs
DuPont upgraded to Buy from Neutral at Goldman Sachs
05/05/21 Wells Fargo
DuPont price target raised to $95 from $90 at Wells Fargo
05/05/21 KeyBanc
DuPont price target raised to $93 from $87 at KeyBanc
DD DuPont
$83.27 /

+1.63 (+2.00%)

DD DuPont
$83.27 /

+1.63 (+2.00%)

DD DuPont
$83.27 /

+1.63 (+2.00%)

Periodicals
Whirlpool stock 'the way to play' home appliances demand, Barron's says » 10:52
05/15/21
05/15
10:52
05/15/21
10:52
WHR

Whirlpool

$246.67 /

+0.24 (+0.10%)

Anyone who has been…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WHR Whirlpool
$246.67 /

+0.24 (+0.10%)

WHR Whirlpool
$246.67 /

+0.24 (+0.10%)

04/23/21 RBC Capital
Whirlpool price target raised to $210 from $201 at RBC Capital
04/15/21 Raymond James
Raymond James says AHAM Q1 U.S. 'core 6' appliance wholesale shipments up 18%
04/07/21 JPMorgan
Whirlpool price target raised to $261 from $258 at JPMorgan
04/07/21 JPMorgan
JPMorgan lays out long and short homebuilding ideas into earnings
WHR Whirlpool
$246.67 /

+0.24 (+0.10%)

WHR Whirlpool
$246.67 /

+0.24 (+0.10%)

On The Fly
Opening Day: E-commerce company Global-e valued at $3.6B in debut » 07:35
05/15/21
05/15
07:35
05/15/21
07:35
VERA

Vera Therapeutics

$11.52 /

-0.22 (-1.87%)

, DBGI

Digital Brands

$3.38 /

-0.49 (-12.66%)

, EJH

E-Home Household Service

$53.05 /

+23.68 (+80.63%)

, SMWB

Similarweb

$21.43 /

+0.16 (+0.75%)

, GLBE

Global-e Online

$26.81 /

+1.31 (+5.14%)

, IPW

iPower

$5.70 /

+0.64 (+12.65%)

, FLGC

Flora Growth

$4.03 /

+0.22 (+5.77%)

, DV

DoubleVerify

$30.87 /

+0.6 (+1.98%)

, PATH

UiPath

$70.48 /

+4.015 (+6.04%)

, NPCE

NeuroPace

$21.01 /

+1.87 (+9.77%)

, RAIN

Rain Therapeutics

$15.15 /

+0.15 (+1.00%)

, SWIM

Latham Group

$31.93 /

+2.34 (+7.91%)

, TMCI

Treace Medical

$29.52 /

+1.775 (+6.40%)

, SQSP

Squarespace

/

+

, QNIU

Qiniu

/

+

, SVFD

Save Foods

$10.75 /

+0.26 (+2.48%)

, RGCB

Regencell Bioscience

/

+

, CMSL

Camposol

/

+

, UBER

Uber

$47.41 /

+2.89 (+6.49%)

, LYFT

Lyft

$49.64 /

+3.6098 (+7.84%)

, SBUX

Starbucks

$111.19 /

+0.73 (+0.66%)

, HCG

Hear.com

/

+

, GNW

Genworth

$4.09 /

+0.215 (+5.55%)

, MS

Morgan Stanley

$87.35 /

+2.47 (+2.91%)

Global-e Online opened 3%…

ShowHide Related Items >><<
UBER Uber
$47.41 /

+2.89 (+6.49%)

SBUX Starbucks
$111.19 /

+0.73 (+0.66%)

RAIN Rain Therapeutics
$15.15 /

+0.15 (+1.00%)

PATH UiPath
$70.48 /

+4.015 (+6.04%)

MS Morgan Stanley
$87.35 /

+2.47 (+2.91%)

LYFT Lyft
$49.64 /

+3.6098 (+7.84%)

GNW Genworth
$4.09 /

+0.215 (+5.55%)

FLGC Flora Growth
$4.03 /

+0.22 (+5.77%)

DV DoubleVerify
$30.87 /

+0.6 (+1.98%)

VERA Vera Therapeutics
$11.52 /

-0.22 (-1.87%)

DBGI Digital Brands
$3.38 /

-0.49 (-12.66%)

EJH E-Home Household Service
$53.05 /

+23.68 (+80.63%)

SMWB Similarweb
$21.43 /

+0.16 (+0.75%)

GLBE Global-e Online
$26.81 /

+1.31 (+5.14%)

IPW iPower
$5.70 /

+0.64 (+12.65%)

FLGC Flora Growth
$4.03 /

+0.22 (+5.77%)

DV DoubleVerify
$30.87 /

+0.6 (+1.98%)

PATH UiPath
$70.48 /

+4.015 (+6.04%)

05/13/21 Berenberg
UiPath initiated with a Hold at Berenberg
NPCE NeuroPace
$21.01 /

+1.87 (+9.77%)

RAIN Rain Therapeutics
$15.15 /

+0.15 (+1.00%)

SWIM Latham Group
$31.93 /

+2.34 (+7.91%)

TMCI Treace Medical
$29.52 /

+1.775 (+6.40%)

SQSP Squarespace
/

+

QNIU Qiniu
/

+

SVFD Save Foods
$10.75 /

+0.26 (+2.48%)

RGCB Regencell Bioscience
/

+

CMSL Camposol
/

+

UBER Uber
$47.41 /

+2.89 (+6.49%)

05/07/21 Truist
James River Group upgraded to Buy from Hold at Truist
05/06/21 Wedbush
Uber price target lowered to $66 from $76 at Wedbush
05/06/21 JPMorgan
JPMorgan boosts Uber target to $74 on continued mobility recovery
05/06/21 Deutsche Bank
Uber price target raised to $85 from $82 at Deutsche Bank
LYFT Lyft
$49.64 /

+3.6098 (+7.84%)

05/14/21 Wedbush
Lyft removed from Best Ideas List at Wedbush
05/10/21
Fly Intel: Top five analyst upgrades
05/10/21 Daiwa
Lyft upgraded to Outperform from Neutral at Daiwa
05/10/21 Daiwa
Lyft upgraded to Outperform from Neutral at Daiwa
SBUX Starbucks
$111.19 /

+0.73 (+0.66%)

04/28/21 Morgan Stanley
Starbucks price target raised to $120 from $110 at Morgan Stanley
04/28/21 MKM Partners
Starbucks price target raised to $125 from $117 at MKM Partners
04/28/21 Wedbush
Starbucks price target raised to $132 from $124 at Wedbush
04/28/21 Credit Suisse
Starbucks price target raised to $125 from $116 at Credit Suisse
HCG Hear.com
/

+

GNW Genworth
$4.09 /

+0.215 (+5.55%)

01/04/21 BTIG
BTIG says investors should remain on sidelines amid Genworth's pullback
MS Morgan Stanley
$87.35 /

+2.47 (+2.91%)

04/21/21
Fly Intel: Top five analyst upgrades
04/21/21 Berenberg
Morgan Stanley upgraded to Buy from Hold at Berenberg
04/20/21 Piper Sandler
Morgan Stanley price target raised to $87 from $82 at Piper Sandler
04/19/21 RBC Capital
Morgan Stanley price target raised to $82 from $78 at RBC Capital
UBER Uber
$47.41 /

+2.89 (+6.49%)

SBUX Starbucks
$111.19 /

+0.73 (+0.66%)

MS Morgan Stanley
$87.35 /

+2.47 (+2.91%)

LYFT Lyft
$49.64 /

+3.6098 (+7.84%)

GNW Genworth
$4.09 /

+0.215 (+5.55%)

  • 14
    May
  • 14
    May
  • 12
    May
  • 11
    May
  • 20
    May
  • 14
    May
  • 14
    May
  • 12
    May
  • 07
    May
  • 12
    May
  • 23
    Apr
  • 23
    Apr
  • 23
    Apr
  • 22
    Apr
  • 21
    Apr
  • 21
    Apr
  • 08
    Jan
UBER Uber
$47.41 /

+2.89 (+6.49%)

SBUX Starbucks
$111.19 /

+0.73 (+0.66%)

MS Morgan Stanley
$87.35 /

+2.47 (+2.91%)

LYFT Lyft
$49.64 /

+3.6098 (+7.84%)

HCG Hear.com
/

+

UBER Uber
$47.41 /

+2.89 (+6.49%)

SWIM Latham Group
$31.93 /

+2.34 (+7.91%)

SQSP Squarespace
/

+

SBUX Starbucks
$111.19 /

+0.73 (+0.66%)

MS Morgan Stanley
$87.35 /

+2.47 (+2.91%)

LYFT Lyft
$49.64 /

+3.6098 (+7.84%)

GNW Genworth
$4.09 /

+0.215 (+5.55%)

GLBE Global-e Online
$26.81 /

+1.31 (+5.14%)

DV DoubleVerify
$30.87 /

+0.6 (+1.98%)

UBER Uber
$47.41 /

+2.89 (+6.49%)

SBUX Starbucks
$111.19 /

+0.73 (+0.66%)

PATH UiPath
$70.48 /

+4.015 (+6.04%)

MS Morgan Stanley
$87.35 /

+2.47 (+2.91%)

LYFT Lyft
$49.64 /

+3.6098 (+7.84%)

GNW Genworth
$4.09 /

+0.215 (+5.55%)

Periodicals
Italy tribunal favors Blackstone in RCS building dispute, Reuters reports » 18:55
05/14/21
05/14
18:55
05/14/21
18:55
BX

Blackstone

$87.45 /

+2.03 (+2.38%)

A Milan arbitral tribunal…

A Milan arbitral tribunal ruled in favor of Blackstone Group in a disputed sale of the headquarters of RCS, rejecting all claims levied by the Italian publisher, Reuters' Claudia Cristoferi reports, citing a court document. Reference Link

ShowHide Related Items >><<
BX Blackstone
$87.45 /

+2.03 (+2.38%)

BX Blackstone
$87.45 /

+2.03 (+2.38%)

04/27/21 Argus
Blackstone price target raised to $100 from $82 at Argus
04/23/21 Barclays
Blackstone price target raised to $95 from $85 at Barclays
04/23/21 Deutsche Bank
Blackstone price target raised to $76 from $66 at Deutsche Bank
04/12/21 Barclays
Blackstone price target raised to $85 from $75 at Barclays
BX Blackstone
$87.45 /

+2.03 (+2.38%)

BX Blackstone
$87.45 /

+2.03 (+2.38%)

BX Blackstone
$87.45 /

+2.03 (+2.38%)

BX Blackstone
$87.45 /

+2.03 (+2.38%)

Hot Stocks
Apellis Pharmaceuticals trading resumes  18:55
05/14/21
05/14
18:55
05/14/21
18:55
APLS

Apellis

$44.25 /

-1.315 (-2.89%)

 
ShowHide Related Items >><<
APLS Apellis
$44.25 /

-1.315 (-2.89%)

APLS Apellis
$44.25 /

-1.315 (-2.89%)

04/16/21
Fly Intel: Top five analyst initiations
04/16/21 Goldman Sachs
Apellis initiated with a Buy at Goldman Sachs
04/14/21 Citi
Apellis year-to-date selloff brings 'very good entry point,' says Citi
03/29/21 JPMorgan
Apellis added to Analyst Focus List with $87 target at JPMorgan
APLS Apellis
$44.25 /

-1.315 (-2.89%)

APLS Apellis
$44.25 /

-1.315 (-2.89%)

APLS Apellis
$44.25 /

-1.315 (-2.89%)

Hot Stocks
Lordstown Motors reschedules release of Q1 financial results to May 24 » 18:42
05/14/21
05/14
18:42
05/14/21
18:42
RIDE

Lordstown Motors

$7.32 /

+0.33 (+4.72%)

Lordstown Motors…

Lordstown Motors announced that it will reschedule the release of its first quarter 2021 financial results, previously scheduled for May 17. The company now intends to report first quarter financial results on Monday, May 24, after the market closes. The company will then host a conference call at 4:30 p.m. Eastern Time.

ShowHide Related Items >><<
RIDE Lordstown Motors
$7.32 /

+0.33 (+4.72%)

RIDE Lordstown Motors
$7.32 /

+0.33 (+4.72%)

05/11/21 B. Riley
B. Riley cuts Workhorse target but says earnings selloff overblown
04/22/21 Morgan Stanley
Lordstown shares have 80% downside in Morgan Stanley bear case
04/22/21
Fly Intel: Top five analyst downgrades
04/22/21 Goldman Sachs
Lordstown Motors downgraded to Neutral from Buy at Goldman Sachs
RIDE Lordstown Motors
$7.32 /

+0.33 (+4.72%)

RIDE Lordstown Motors
$7.32 /

+0.33 (+4.72%)

RIDE Lordstown Motors
$7.32 /

+0.33 (+4.72%)

RIDE Lordstown Motors
$7.32 /

+0.33 (+4.72%)

Hot Stocks
Apellis announces FDA approval of EMPAVELI » 18:26
05/14/21
05/14
18:26
05/14/21
18:26
APLS

Apellis

$44.25 /

-1.315 (-2.89%)

Apellis Pharmaceuticals…

Apellis Pharmaceuticals announced that the U.S. Food and Drug Administration has approved EMPAVELI, the first and only targeted C3 therapy for treatment of adults with paroxysmal nocturnal hemoglobinuria. EMPAVELI is approved for use in adults with PNH who are treatment naive as well as patients switching from the C5 inhibitors Soliris and Ultomiris. "EMPAVELI has the potential to improve the lives of patients with PNH by increasing hemoglobin and reducing blood transfusion requirements," said Olga Frankfurt, M.D., PEGASUS study investigator and associate professor in the department of medicine, division of hematology and oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University. "Through my work as an investigator on the PEGASUS study, I was excited to see EMPAVELI providing broad control of PNH."

ShowHide Related Items >><<
APLS Apellis
$44.25 /

-1.315 (-2.89%)

APLS Apellis
$44.25 /

-1.315 (-2.89%)

04/16/21
Fly Intel: Top five analyst initiations
04/16/21 Goldman Sachs
Apellis initiated with a Buy at Goldman Sachs
04/14/21 Citi
Apellis year-to-date selloff brings 'very good entry point,' says Citi
03/29/21 JPMorgan
Apellis added to Analyst Focus List with $87 target at JPMorgan
APLS Apellis
$44.25 /

-1.315 (-2.89%)

APLS Apellis
$44.25 /

-1.315 (-2.89%)

APLS Apellis
$44.25 /

-1.315 (-2.89%)

Syndicate
ArcLight Clean Transition: SEC declares registration statement effective » 18:26
05/14/21
05/14
18:26
05/14/21
18:26
ACTC

ArcLight Clean Transition

$13.96 /

+0.57 (+4.26%)

ArcLight Clean Transition…

ArcLight Clean Transition announced that the U.S. SEC has declared effective the registration statement on Form S-4 of ArcLight (File No. 333-252674), which includes a definitive proxy statement/prospectus in connection with ArcLight's extraordinary general meeting of shareholders to consider the previously announced proposed business combination with Proterra. ArcLight began mailing the definitive proxy statement/prospectus and other relevant documents to shareholders of ArcLight as of the record date established for voting on the Business Combination.

ShowHide Related Items >><<
ACTC ArcLight Clean Transition
$13.96 /

+0.57 (+4.26%)

ACTC ArcLight Clean Transition
$13.96 /

+0.57 (+4.26%)

ACTC ArcLight Clean Transition
$13.96 /

+0.57 (+4.26%)

Hot Stocks
Fears Nachawati law firm says appellate ruling deals 'blow' to Bayer efforts » 18:24
05/14/21
05/14
18:24
05/14/21
18:24
BAYRY

Bayer

$16.68 /

-0.645 (-3.72%)

A federal appellate…

A federal appellate ruling upholding findings that Bayer AG's Monsanto Roundup weed killer caused a California man's non-Hodgkins lymphoma cancer deals a blow to efforts by Bayer AG to push through a "flawed" settlement of thousands of pending cancer lawsuits, trial lawyers with Dallas-based Fears Nachawati Law Firm said. Friday's ruling stems from a 2019 jury verdict finding that plaintiff Edwin Hardeman developed non-Hodgkins lymphoma after exposure to Roundup. The verdict included $5M in compensatory damages and $75M in punitive damages, which were later reduced to $20M. The ruling has implications for Bayer's efforts to settle more than 90,000 pending cancer lawsuits, which have drawn criticism from thousands of plaintiffs. Among other things, the settlement would allow Bayer to continue selling Roundup but limit legal options for individuals diagnosed with cancer in the future. A hearing on the settlement is set for May 19. "We now have a federal appellate court supporting evidence that Roundup causes cancer and that Bayer had a duty to warn consumers," Nachawati said. "Shareholders need to know that these lawsuits will not stop until Bayer makes a meaningful settlement offer."

ShowHide Related Items >><<
BAYRY Bayer
$16.68 /

-0.645 (-3.72%)

BAYRY Bayer
$16.68 /

-0.645 (-3.72%)

05/14/21 Berenberg
Bayer price target raised to EUR 74 from EUR 68 at Berenberg
05/13/21 Credit Suisse
Bayer price target raised to EUR 60 from EUR 56 at Credit Suisse
05/13/21 Bryan Garnier
Bayer upgraded to Neutral from Sell at Bryan Garnier
05/06/21 Citi
Citi opens 'Positive Catalyst Watch' on Bayer
BAYRY Bayer
$16.68 /

-0.645 (-3.72%)

BAYRY Bayer
$16.68 /

-0.645 (-3.72%)

BAYRY Bayer
$16.68 /

-0.645 (-3.72%)

Hot Stocks
Corporacion America Airport reports April passenger traffic up 1,342.4% y/y » 18:17
05/14/21
05/14
18:17
05/14/21
18:17
CAAP

Corporacion America Airport

$5.81 /

+0.16 (+2.83%)

Corporacion America…

Corporacion America Airports reported a 1,342.4% YoY passenger traffic growth in April 2021, and 75.7% decline when compared to the same period of 2019. Total passenger traffic in April 2021 grew 13.4x YoY compared to the same period last year, reflecting easier comparisons as April 2020 was the first month fully impacted by the COVID-19 pandemic. When compared to 2019, overall passenger traffic declined 60.4%, while international and domestic passenger traffic dropped 79.8% and 52.7%, respectively, impacted by the COVID-19 pandemic on air travel across all countries of operations.

ShowHide Related Items >><<
CAAP Corporacion America Airport
$5.81 /

+0.16 (+2.83%)

CAAP Corporacion America Airport
$5.81 /

+0.16 (+2.83%)

CAAP Corporacion America Airport
$5.81 /

+0.16 (+2.83%)

CAAP Corporacion America Airport
$5.81 /

+0.16 (+2.83%)

Periodicals
BlackRock to ask U.S. workers to return to offices in September, Bloomberg says » 18:15
05/14/21
05/14
18:15
05/14/21
18:15
BLK

BlackRock

$856.93 /

+18.74 (+2.24%)

BlackRock plans to ask…

BlackRock plans to ask U.S. staff to return to offices in September, when it will initiate a trial period allowing some remote work each week, Bloomberg's Annie Massa reports, citing a spokesman for the company. The asset manager plans to allow up to two days per week of remote work on average for U.S. employees, and will ask workers to begin "re-acclimating" to office work periodically in July and August if they feel comfortable doing so, Massa says. Staff can continue working remotely full-time through June 30, the author notes. Reference Link

ShowHide Related Items >><<
BLK BlackRock
$856.93 /

+18.74 (+2.24%)

BLK BlackRock
$856.93 /

+18.74 (+2.24%)

04/19/21 RBC Capital
PNC Financial price target raised to $190 from $161 at RBC Capital
04/16/21 Credit Suisse
BlackRock price target raised to $984 from $949 at Credit Suisse
04/16/21 Deutsche Bank
BlackRock price target raised to $912 from $847 at Deutsche Bank
04/16/21 Citi
BlackRock price target raised to $1,000 from $950 at Citi
BLK BlackRock
$856.93 /

+18.74 (+2.24%)

BLK BlackRock
$856.93 /

+18.74 (+2.24%)

BLK BlackRock
$856.93 /

+18.74 (+2.24%)

Periodicals
BlackRock to ask U.S. workers to return to offices in September, Bloomberg says » 17:54
05/14/21
05/14
17:54
05/14/21
17:54
BLK

BlackRock

$856.93 /

+18.74 (+2.24%)

BlackRock plans to ask…

BlackRock plans to ask U.S. staff to return to offices in September, when it will initiate a trial period allowing some remote work each week, Bloomberg's Annie Massa reports, citing a spokesman for the company.

ShowHide Related Items >><<
BLK BlackRock
$856.93 /

+18.74 (+2.24%)

BLK BlackRock
$856.93 /

+18.74 (+2.24%)

04/19/21 RBC Capital
PNC Financial price target raised to $190 from $161 at RBC Capital
04/16/21 Credit Suisse
BlackRock price target raised to $984 from $949 at Credit Suisse
04/16/21 Deutsche Bank
BlackRock price target raised to $912 from $847 at Deutsche Bank
04/16/21 Citi
BlackRock price target raised to $1,000 from $950 at Citi
BLK BlackRock
$856.93 /

+18.74 (+2.24%)

BLK BlackRock
$856.93 /

+18.74 (+2.24%)

BLK BlackRock
$856.93 /

+18.74 (+2.24%)

Hot Stocks
PNC receives regulatory approval for BBVA USA takeover » 17:49
05/14/21
05/14
17:49
05/14/21
17:49
PNC

PNC Financial

$199.36 /

+3.34 (+1.70%)

, BBVA

BBVA

$6.16 /

+0.195 (+3.27%)

The PNC Financial…

The PNC Financial Services Group, Inc. (PNC) announced receipt of regulatory approval from the Board of Governors of the Federal Reserve System and the Office of the Comptroller of the Currency to complete the previously announced acquisition of BBVA USA Bancshares, Inc. (BBVA), including its U.S. banking subsidiary, BBVA USA. The regulatory approval process also included approvals from the Banking Departments of the States of Alabama and Texas. No further regulatory approvals are required to complete the acquisition and merger of PNC Bank and BBVA USA. The acquisition is anticipated to close June 1, 2021, pending satisfaction of customary closing conditions. "We are pleased to have received regulatory approval of our acquisition that will accelerate our growth trajectory and drive long-term shareholder value," said William S. Demchak, PNC chairman, president and chief executive officer. "With common cultures and values and a shared commitment to our customers, employees and communities, we look forward to bringing PNC's industry-leading technology and innovative products and services to new markets and clients."

ShowHide Related Items >><<
PNC PNC Financial
$199.36 /

+3.34 (+1.70%)

BBVA BBVA
$6.16 /

+0.195 (+3.27%)

PNC PNC Financial
$199.36 /

+3.34 (+1.70%)

05/10/21 Raymond James
PNC Financial upgraded to Outperform from Market Perform at Raymond James
05/06/21 Wells Fargo
PNC Financial price target raised to $230 from $197 at Wells Fargo
04/20/21 Citi
PNC Financial price target raised to $210 from $179 at Citi
04/19/21 Stephens
PNC Financial price target raised to $195 from $190 at Stephens
BBVA BBVA
$6.16 /

+0.195 (+3.27%)

05/04/21 RBC Capital
BBVA price target raised to EUR 5.30 from EUR 5.10 at RBC Capital
05/04/21 UBS
BBVA price target raised to EUR 4.85 from EUR 4.60 at UBS
05/04/21 Morgan Stanley
BBVA price target raised to EUR 5.20 from EUR 4.90 at Morgan Stanley
05/04/21 Credit Suisse
BBVA price target raised to EUR 4.50 from EUR 4.30 at Credit Suisse
PNC PNC Financial
$199.36 /

+3.34 (+1.70%)

BBVA BBVA
$6.16 /

+0.195 (+3.27%)

PNC PNC Financial
$199.36 /

+3.34 (+1.70%)

PNC PNC Financial
$199.36 /

+3.34 (+1.70%)

BBVA BBVA
$6.16 /

+0.195 (+3.27%)

Syndicate
Metalla Royalty & Streaming announces new at-the-market equity program » 17:34
05/14/21
05/14
17:34
05/14/21
17:34
MTA

Metalla Royalty & Streaming

$9.67 /

+0.23 (+2.44%)

Metalla Royalty &…

Metalla Royalty & Streaming Ltd. announced that it has entered into a new equity distribution agreement with a syndicate of agents including BMO Nesbitt Burns, PI Financial Corp, and Scotiabank, as the Canadian agents, and BMO Capital Markets Corp. and Scotiabank, as the United States agents, for a new at-the-market equity program. The distribution agreement will replace the company's previous equity distribution agreement, which has been terminated, and will allow the company to distribute up to $35.0M of common shares of the company under the new ATM Program. The shares will be issued by the company to the public from time to time, through the agents, at the company's discretion. The net proceeds of any such sales under the new ATM program will be used to finance the future purchase of streams and royalties by the company and for general working capital purposes.

ShowHide Related Items >><<
MTA Metalla Royalty & Streaming
$9.67 /

+0.23 (+2.44%)

05/11/21 Roth Capital
Metalla Royalty & Streaming upgraded to Buy from Neutral at Roth Capital
03/16/21 Cantor Fitzgerald
Metalla Royalty & Streaming upgraded to Buy from Hold at Cantor Fitzgerald
03/01/21 BMO Capital
Metalla Royalty & Streaming initiated with a Market Perform at BMO Capital
12/16/20 Roth Capital
Metalla Royalty & Streaming initiated with a Neutral at Roth Capital
MTA Metalla Royalty & Streaming
$9.67 /

+0.23 (+2.44%)

Hot Stocks
Charles Schwab chairman sells 44,380 common shares » 17:34
05/14/21
05/14
17:34
05/14/21
17:34
SCHW

Charles Schwab

$73.27 /

+2.83 (+4.02%)

In a regulatory filing,…

In a regulatory filing, Charles Schwab chairman Charles Schwab disclosed the sale of 44,380 common shares of the company on May 14 at a price of $72 per share.

ShowHide Related Items >><<
SCHW Charles Schwab
$73.27 /

+2.83 (+4.02%)

SCHW Charles Schwab
$73.27 /

+2.83 (+4.02%)

05/13/21 JPMorgan
Charles Schwab price target raised to $84 from $82 at JPMorgan
04/27/21
Fly Intel: Top five analyst upgrades
04/27/21 Credit Suisse
Credit Suisse upgrades Schwab, sees 50% return potential in two years
04/27/21 Credit Suisse
Charles Schwab upgraded to Outperform from Neutral at Credit Suisse
SCHW Charles Schwab
$73.27 /

+2.83 (+4.02%)

SCHW Charles Schwab
$73.27 /

+2.83 (+4.02%)

SCHW Charles Schwab
$73.27 /

+2.83 (+4.02%)

SCHW Charles Schwab
$73.27 /

+2.83 (+4.02%)

Syndicate
Pyxis Tankers files $250M mixed securities shelf  17:31
05/14/21
05/14
17:31
05/14/21
17:31
PXS

Pyxis Tankers

/

+

 
ShowHide Related Items >><<
PXS Pyxis Tankers
/

+

PXS Pyxis Tankers
/

+

02/17/21 Noble Capital
Pyxis Tankers downgraded to Market Perform from Outperform at Noble Capital
Hot Stocks
Perspecta awarded $473.8M DSCA transaction agreement » 17:21
05/14/21
05/14
17:21
05/14/21
17:21
PRSP

Perspecta

$29.34 /

+ (+0.00%)

Perspecta has been…

Perspecta has been awarded an enterprise information technology, or EIT, application development services production other transaction agreement with a base period of 12 months and four optional 12-month periods. The total estimated agreement value at the time of award is $473.8M, with a not-to-exceed value of $500,000,000 for all periods of performance and contract line item numbers. This agreement is based upon the successful completion of the Defense Counterintelligence and Security Agency's, or DCSA, security enterprise architecture and data analytics prototype other transaction agreement, which was competitively awarded to Perspecta on May 14, 2019. The transaction continues the development and operations of the prototype solutions pertaining to major components of a comprehensive IT system for managing all background investigations and security clearance adjudications for federal employees and contractors. Through use of the scaled agile framework, or SAFe, processes, this transaction will support the development, enhancement and expansion of defense business system capabilities throughout operations of the EIT application. Work will be performed within the National Capital Region surrounding Fort Meade, Maryland. It has an estimated completion date of May 14, 2026. FY21 Budget Activity 08, DCSA funds for $29.34Mwere obligated at the time of the award. DCSA Acquisition and Contracting is the contracting activity.

ShowHide Related Items >><<
PRSP Perspecta
$29.34 /

+ (+0.00%)

PRSP Perspecta
$29.34 /

+ (+0.00%)

02/08/21 Stifel
Stifel cuts Perspecta rating to Hold as results unlikely to attract new bidders
02/08/21 Stifel
Perspecta downgraded to Hold from Buy at Stifel
01/27/21 Stifel
CACI 'very likely' to bid on Perspecta as well, says Stifel
06/12/20 William Blair
William Blair sees near-term takeover of Perspecta as unlikely despite Jana news
PRSP Perspecta
$29.34 /

+ (+0.00%)

PRSP Perspecta
$29.34 /

+ (+0.00%)

PRSP Perspecta
$29.34 /

+ (+0.00%)

PRSP Perspecta
$29.34 /

+ (+0.00%)

Hot Stocks
Jack Dorsey says Bitcoin 'changes everything for the better' » 17:05
05/14/21
05/14
17:05
05/14/21
17:05
TWTR

Twitter

$51.74 /

+1.63 (+3.25%)

, SQ

Square

$207.55 /

+10.43 (+5.29%)

, BTC

Bitcoin

/

+

, BITCOIN

Bitcoin

/

+

, $BTC

Bitcoin

/

+

Jack Dorsey, CEO of both…

Jack Dorsey, CEO of both Twitter (TWTR) and Square (SQ), said in a tweet that Bitcoin changes "everything" for the better. " "And we will forever work to make bitcoin better," Dorsey said in a response to a tweet for Square CFO Amrita Ahuja, saying the company's bitcoin strategy "hasn't changed." Reference Link

ShowHide Related Items >><<
TWTR Twitter
$51.74 /

+1.63 (+3.25%)

SQ Square
$207.55 /

+10.43 (+5.29%)

BTC Bitcoin
/

+

BITCOIN Bitcoin
/

+

TWTR Twitter
$51.74 /

+1.63 (+3.25%)

05/10/21 Citi
Twitter price target lowered to $58 from $80 at Citi
05/03/21 BMO Capital
Twitter price target lowered to $65 from $80 at BMO Capital
04/30/21 MKM Partners
Twitter price target lowered to $83 from $95 at MKM Partners
04/30/21 JPMorgan
Twitter earnings selloff a buying opportunity, says JPMorgan
SQ Square
$207.55 /

+10.43 (+5.29%)

05/10/21 BMO Capital
Square price target raised to $269 from $237 at BMO Capital
05/07/21 JPMorgan
Square price target raised to $300 from $250 at JPMorgan
05/07/21 Morgan Stanley
Square price target raised to $254 from $245 at Morgan Stanley
05/07/21 Credit Suisse
Square price target raised to $300 from $290 at Credit Suisse
BTC Bitcoin
/

+

04/27/21 Roth Capital
Regulatory credits, bitcoin fuel Tesla Q1 headline beat, says Roth Capital
04/15/21 Morgan Stanley
WisdomTree Bitcoin ETP cross-listing could speed up growth, says Morgan Stanley
01/13/21 Standpoint Research
Bitcoin could hit $112,000 this year, says Standpoint Research
BITCOIN Bitcoin
/

+

05/13/21 BTIG
BTIG sees Binance news as 'net positive' for Coinbase
$BTC Bitcoin
/

+

TWTR Twitter
$51.74 /

+1.63 (+3.25%)

SQ Square
$207.55 /

+10.43 (+5.29%)

BTC Bitcoin
/

+

TWTR Twitter
$51.74 /

+1.63 (+3.25%)

SQ Square
$207.55 /

+10.43 (+5.29%)

BTC Bitcoin
/

+

BITCOIN Bitcoin
/

+

TWTR Twitter
$51.74 /

+1.63 (+3.25%)

SQ Square
$207.55 /

+10.43 (+5.29%)

BTC Bitcoin
/

+

BITCOIN Bitcoin
/

+

TWTR Twitter
$51.74 /

+1.63 (+3.25%)

SQ Square
$207.55 /

+10.43 (+5.29%)

Hot Stocks
Apellis Pharmaceuticals trading halted, news pending  17:03
05/14/21
05/14
17:03
05/14/21
17:03
APLS

Apellis

$44.25 /

-1.315 (-2.89%)

 
ShowHide Related Items >><<
APLS Apellis
$44.25 /

-1.315 (-2.89%)

APLS Apellis
$44.25 /

-1.315 (-2.89%)

04/16/21
Fly Intel: Top five analyst initiations
04/16/21 Goldman Sachs
Apellis initiated with a Buy at Goldman Sachs
04/14/21 Citi
Apellis year-to-date selloff brings 'very good entry point,' says Citi
03/29/21 JPMorgan
Apellis added to Analyst Focus List with $87 target at JPMorgan
APLS Apellis
$44.25 /

-1.315 (-2.89%)

APLS Apellis
$44.25 /

-1.315 (-2.89%)

APLS Apellis
$44.25 /

-1.315 (-2.89%)

Syndicate
Myomo files $100M mixed securities shelf  17:03
05/14/21
05/14
17:03
05/14/21
17:03
MYO

Myomo

$9.10 /

+0.14 (+1.56%)

 
ShowHide Related Items >><<
MYO Myomo
$9.10 /

+0.14 (+1.56%)

MYO Myomo
$9.10 /

+0.14 (+1.56%)

01/11/21 Sidoti
Myomo price target raised to $14 from $11 at Sidoti
11/11/20 Roth Capital
Myomo upgraded to Buy on MyoPro momentum at Roth Capital
11/11/20 Roth Capital
Myomo upgraded to Buy from Neutral at Roth Capital
09/16/20 Roth Capital
Myomo provider status authorization 'an incremental positive,' says Roth Capital
MYO Myomo
$9.10 /

+0.14 (+1.56%)

Syndicate
RCI Hospitality files $100M mixed securities shelf  17:02
05/14/21
05/14
17:02
05/14/21
17:02
RICK

RCI Hospitality

$77.41 /

+7.12 (+10.13%)

 
ShowHide Related Items >><<
RICK RCI Hospitality
$77.41 /

+7.12 (+10.13%)

RICK RCI Hospitality
$77.41 /

+7.12 (+10.13%)

01/12/21 Sidoti
RCI Hospitality price target raised to $42 from $35 at Sidoti
09/08/20 Sidoti
RCI Hospitality price target raised to $29 from $27 at Sidoti
RICK RCI Hospitality
$77.41 /

+7.12 (+10.13%)

RICK RCI Hospitality
$77.41 /

+7.12 (+10.13%)

Hot Stocks
Trian takes stake in Ferguson, adds to positions in Invesco, GE » 17:00
05/14/21
05/14
17:00
05/14/21
17:00
FERG

Ferguson

$131.39 /

+1.91 (+1.48%)

, IVZ

Invesco

$27.95 /

+0.82 (+3.02%)

, GE

General Electric

$13.25 /

+0.29 (+2.24%)

, MDLZ

Mondelez

$62.40 /

+ (+0.00%)

, PG

Procter & Gamble

$138.00 /

+0.24 (+0.17%)

, SYY

Sysco

$84.01 /

+0.9 (+1.08%)

, CMCSA

Comcast

$58.67 /

+1.29 (+2.25%)

Nelson Peltz's Trian…

Nelson Peltz's Trian Fund Management disclosed in an SEC filing its holdings as of March 31, 2021. Trian's one new buy during the first quarter was Ferguson (FERG). Trian increased its stake in two holdings, including by size of previous position, Invesco (IVZ) and General Electric (GE). Trian reduced its stake in two holdings, including by size of previous position, Mondelez (MDLZ) and Procter & Gamble (PG). Trian's top holdings as of March 31, in order of size, were Sysco (SYY), Ferguson, Procter & Gamble, Comcast (CMCSA), and Invesco.

ShowHide Related Items >><<
SYY Sysco
$84.01 /

+0.9 (+1.08%)

PG Procter & Gamble
$138.00 /

+0.24 (+0.17%)

MDLZ Mondelez
$62.40 /

+ (+0.00%)

IVZ Invesco
$27.95 /

+0.82 (+3.02%)

GE General Electric
$13.25 /

+0.29 (+2.24%)

CMCSA Comcast
$58.67 /

+1.29 (+2.25%)

FERG Ferguson
$131.39 /

+1.91 (+1.48%)

03/18/21 Berenberg
Ferguson price target raised to 7,500 GBp from 7,300 GBp at Berenberg
03/18/21 Credit Suisse
Ferguson price target raised to 8,975 GBp from 8,859 GBp at Credit Suisse
03/18/21 Morgan Stanley
Ferguson price target raised to 9,500 GBp from 9,060 GBp at Morgan Stanley
03/17/21 Barclays
Ferguson price target raised to 9,500 GBp from 9,000 GBp at Barclays
IVZ Invesco
$27.95 /

+0.82 (+3.02%)

04/09/21 Deutsche Bank
Invesco price target raised to $31 from $28 at Deutsche Bank
01/28/21
Fly Intel: Top five analyst upgrades
01/28/21
Invesco upgraded to Buy from Neutral at UBS
01/28/21 UBS
Invesco upgraded to Buy from Neutral at UBS
GE General Electric
$13.25 /

+0.29 (+2.24%)

05/14/21 Citi
General Electric reinstated with a Buy at Citi
04/29/21 Stephens
AerCap named a Best Idea at Stephens
04/28/21 Deutsche Bank
General Electric price target raised to $15 from $14 at Deutsche Bank
04/27/21 JPMorgan
General Electric should pull back after 'mixed' quarter, says JPMorgan
MDLZ Mondelez
$62.40 /

+ (+0.00%)

04/28/21 Deutsche Bank
Mondelez price target raised to $70 from $67 at Deutsche Bank
02/16/21 Goldman Sachs
Goldman says Mondelez CAGNY presentation 'lends more credibility' to ambitions
01/22/21 Deutsche Bank
Mondelez price target raised to $66 from $64 at Deutsche Bank
01/12/21 Jefferies
Mondelez price target raised to $66 from $62 at Jefferies
PG Procter & Gamble
$138.00 /

+0.24 (+0.17%)

04/21/21
Fly Intel: Top five analyst downgrades
04/21/21 Roth Capital
PureCycle Technologies initiated with a Buy at Roth Capital
04/21/21 Citi
Procter & Gamble downgraded to Neutral from Buy at Citi
04/16/21 JPMorgan
Procter & Gamble price target lowered to $148 from $153 at JPMorgan
SYY Sysco
$84.01 /

+0.9 (+1.08%)

04/27/21 Wells Fargo
Sysco price target raised to $95 from $89 at Wells Fargo
04/12/21 JPMorgan
Sysco price target raised to $85 from $80 at JPMorgan
03/18/21 Piper Sandler
Sysco price target raised to $86 from $82 at Piper Sandler
03/15/21 JPMorgan
Sysco price target raised to $80 from $75 at JPMorgan
CMCSA Comcast
$58.67 /

+1.29 (+2.25%)

05/04/21 Deutsche Bank
Comcast price target raised to $65 from $60 at Deutsche Bank
05/03/21 Evercore ISI
Comcast price target raised to $60 from $56 at Evercore ISI
05/03/21 BofA
BofA adds Disney and Avalara, removes Comcast and Netflix from U.S. 1 List
04/30/21
Fly Intel: Top five analyst upgrades
SYY Sysco
$84.01 /

+0.9 (+1.08%)

PG Procter & Gamble
$138.00 /

+0.24 (+0.17%)

MDLZ Mondelez
$62.40 /

+ (+0.00%)

IVZ Invesco
$27.95 /

+0.82 (+3.02%)

GE General Electric
$13.25 /

+0.29 (+2.24%)

CMCSA Comcast
$58.67 /

+1.29 (+2.25%)

SYY Sysco
$84.01 /

+0.9 (+1.08%)

PG Procter & Gamble
$138.00 /

+0.24 (+0.17%)

MDLZ Mondelez
$62.40 /

+ (+0.00%)

IVZ Invesco
$27.95 /

+0.82 (+3.02%)

GE General Electric
$13.25 /

+0.29 (+2.24%)

CMCSA Comcast
$58.67 /

+1.29 (+2.25%)

SYY Sysco
$84.01 /

+0.9 (+1.08%)

PG Procter & Gamble
$138.00 /

+0.24 (+0.17%)

MDLZ Mondelez
$62.40 /

+ (+0.00%)

GE General Electric
$13.25 /

+0.29 (+2.24%)

CMCSA Comcast
$58.67 /

+1.29 (+2.25%)

SYY Sysco
$84.01 /

+0.9 (+1.08%)

PG Procter & Gamble
$138.00 /

+0.24 (+0.17%)

MDLZ Mondelez
$62.40 /

+ (+0.00%)

IVZ Invesco
$27.95 /

+0.82 (+3.02%)

GE General Electric
$13.25 /

+0.29 (+2.24%)

CMCSA Comcast
$58.67 /

+1.29 (+2.25%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.